Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures.

Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
 
Invetech configures scalable automated GMP manufacturing systems for cell-based products. This includes our formulation and fill automated systems and our (to be launched) counterflow centrifuge product (CFC).
 
Our formulation and fill systems focus on the formulation of large-scale culture media, cell products for cryopreservation, automated bag-filling of cell products (both autologous and allogeneic) and packaging of viral vector products.